Enabling Precision Medicine for Breast Cancer Patients
Approximately every 2 minutes, a woman in the U.S. is diagnosed with breast cancer1. This high prevalence has led to rigorous standards of practice, from diagnosis to treatment.
Precision medicine reduces unnecessary risks to patients including hazardous side effects as well as ineffective treatments (“trial and error” medicine).
Talking Cancer: Conversations with Trailblazers, Advocates, Patients and Medical Ambassadors
As a premier reference lab and global pharma services organization that runs over a million oncology tests annually, NeoGenomics Laboratories, Inc.
Jemperli blog post - please share your thoughts!
We were glad to see FDA’s combined approval for GSK’s Jemperli (dostarlimab) and Ventana’s MMR RxDx for recurrent or advanced endometrial cancer back in April.
Biomarker Types and CDx Biomarkers
The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases.
Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy.
TriCon 2021 Perspective
It was no surprise that Molecular Med Tri-Con 2021 was a virtual event this year.
Why does IHC remain so popular for CDx development?
The topic of IHC came up recently. Specifically, why is it used so frequently for companion diagnostic development.